[ad_1]
Researchers are developing a surprisingly intractable new asthma therapy and are relatively advanced. It is also said that it acts on asthma, not caused by allergies, but by exhaust gases or tobacco smoke.
In addition to drugs that dilate the bronchi and inhibit inflammation, monoclonal antibodies against asthma were introduced a few years ago. These proteins neutralize the individual substances that trigger asthma.
Unlike other drugs in this category, the new biotech drug "tezepelumab" is expected to be generally effective because its effect interferes very early in the processes leading to inflammation. [19659004] Significantly better than placebo
A study involved 584 asthmatic patients who were unable to control seizures with conventional medications. Patients were treated with tezepelumab at three different doses or placebo. The three doses were found effective
The annual rate of asthma attacks decreased by about one-third in the placebo group, but by about two-thirds among those actually treated with the new drug. The effect was relatively rapid and persisted throughout the 52-week treatment period
According to the researchers, the monoclonal antibody is effective not only in asthma caused by allergies, but also in the form of tobacco smoke, diesel exhaust gas or viruses. In addition, the treatment has turned out to be side effects; there were only a few treatment stops. However, the results of large-scale efficacy studies are still pending.
science.ORF.at
More on this subject:
Source link
